REGN reversal playNASDAQ:REGN shows evidence of a price recovery underway as illustrated by momentum indicators and volumn oscillator on the daily. This is further backed up by encouraging signals on both lower and highe timeframes.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
38.6 EUR
4.26 B EUR
13.72 B EUR
104.06 M
About Regeneron Pharmaceuticals, Inc.
Sector
Industry
CEO
Leonard S. Schleifer
Website
Headquarters
Tarrytown
Founded
1988
FIGI
BBG000HCYZV5
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
REGNan upward trend in the prices of an industry's stocks or the overall rise in broad market indices, characterized by high investor confidence
REGN: Second Attempt at Strong Support with 1/18 Risk/RewardNASDAQ:REGN is displaying a strong historical bullish trend and is currently offering a potential buying opportunity. After a recent pullback , the stock has reached a key support level , providing a favorable entry point. The risk/reward ratio is highly attractive, with a 1/18 potential to th
REGN Stock - A Strong Buy OpportunityNASDAQ:REGN is in a historical bullish trend , and right now offers a potential buying opportunity:
Discount at Strong Support : After a pullback, the stock has reached a key support level , providing a good entry point.
Excellent Risk/Reward : With a 1:14 ratio to the all-time high (ATH) ,
The weekly $REGN - oversold and at significant potenial demand The weekly NASDAQ:REGN is at a crucial level that offers a good R/R. Oversold and stretched to the downside could offer a significant bounce from these levels.
Not financial advise!!
NASDAQ-REGN at a Crossroads: Breakdown or Breakout?The Market’s Dilemma: Is REGN Ready for a Reversal?
The biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) is hovering at a critical juncture. Trading at $672.98, the stock has plummeted 44.4% from its all-time high of $1211.19 just five months ago. With the RSI at 38.8, the market is edging t
$REGN LongThis is just my observation, but not an advice.
Technical:
REGN touched its two strong trendline since 2020 and 2021.
REGN reached the 50% correction since 2020.
REGN is oversold daily and weekly.
A significant divergence is observable on daily chart.
Price touched SMA 200.
Fundamental:
P/E: 16
REGN is oversold (the most since 1998)🐂 Trade Idea: Long - REGN
🔥 Account Risk: 20.00%
📈 Recommended Product: Stock
🔍 Entry: +/- 738.00
🐿 DCA: No
😫 Stop-Loss: 660.00
🎯 Take-Profit #1: 1,200.00 (50%)
🎯 Trail Rest: Yes
🚨🚨🚨 Important: Don’t forget to always wait for strong confirmation once possible entry zone is reached. Trade ide
REGN Potential key support areaPlease pay close attention to this crucial support level. It previously served as a significant resistance level and also represented a period of market equilibrium and concentration.
REGNabove 1024 heading to 1065
an upward trend in the prices of an industry's stocks or the overall rise in broad market indices, characterized by high investor confidence
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
8.03%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
5.41%
Maturity date
Sep 15, 2030
See all RGO bonds
Curated watchlists where RGO is featured.
Related stocks
Frequently Asked Questions
The current price of RGO is 490.5 EUR — it has increased by 0.27% in the past 24 hours. Watch REGENERON PHARMAC.DL-,001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange REGENERON PHARMAC.DL-,001 stocks are traded under the ticker RGO.
RGO stock has fallen by −6.57% compared to the previous week, the month change is a −1.59% fall, over the last year REGENERON PHARMAC.DL-,001 has showed a −44.64% decrease.
We've gathered analysts' opinions on REGENERON PHARMAC.DL-,001 future price: according to them, RGO price has a max estimate of 864.45 EUR and a min estimate of 472.40 EUR. Watch RGO chart and read a more detailed REGENERON PHARMAC.DL-,001 stock forecast: see what analysts think of REGENERON PHARMAC.DL-,001 and suggest that you do with its stocks.
RGO stock is 1.47% volatile and has beta coefficient of 0.72. Track REGENERON PHARMAC.DL-,001 stock price on the chart and check out the list of the most volatile stocks — is REGENERON PHARMAC.DL-,001 there?
Today REGENERON PHARMAC.DL-,001 has the market capitalization of 50.76 B, it has decreased by −3.76% over the last week.
Yes, you can track REGENERON PHARMAC.DL-,001 financials in yearly and quarterly reports right on TradingView.
REGENERON PHARMAC.DL-,001 is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
RGO earnings for the last quarter are 7.60 EUR per share, whereas the estimation was 7.97 EUR resulting in a −4.66% surprise. The estimated earnings for the next quarter are 7.62 EUR per share. See more details about REGENERON PHARMAC.DL-,001 earnings.
REGENERON PHARMAC.DL-,001 revenue for the last quarter amounts to 2.80 B EUR, despite the estimated figure of 3.00 B EUR. In the next quarter, revenue is expected to reach 2.94 B EUR.
RGO net income for the last quarter is 747.52 M EUR, while the quarter before that showed 886.48 M EUR of net income which accounts for −15.68% change. Track more REGENERON PHARMAC.DL-,001 financial stats to get the full picture.
Yes, RGO dividends are paid quarterly. The last dividend per share was 0.84 EUR. As of today, Dividend Yield (TTM)% is 0.17%. Tracking REGENERON PHARMAC.DL-,001 dividends might help you take more informed decisions.
REGENERON PHARMAC.DL-,001 dividend yield was 0.00% in 2024, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of May 10, 2025, the company has 15.11 K employees. See our rating of the largest employees — is REGENERON PHARMAC.DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMAC.DL-,001 EBITDA is 4.12 B EUR, and current EBITDA margin is 32.79%. See more stats in REGENERON PHARMAC.DL-,001 financial statements.
Like other stocks, RGO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMAC.DL-,001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REGENERON PHARMAC.DL-,001 technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REGENERON PHARMAC.DL-,001 stock shows the sell signal. See more of REGENERON PHARMAC.DL-,001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.